🟢 Tempus AI is trading 6.29% up today as Merck–Moderna trial success validates Personalis-linked sequencing

Tempus AI is trading 6.29% up now at $65.11 as investors continue rewarding Wednesday’s landmark Merck–Moderna cancer-vaccine trial results.

• Phase 3 success validated sequencing technology connected to Tempus AI’s $1.5 billion Personalis acquisition, supporting renewed investor confidence in its precision-oncology strategy.
• Despite weaker broader-market conditions, company-specific enthusiasm remains the primary catalyst.
• Shares closed at $61.25, up 24.09%, on August 19; the August 20 gain continued that repricing. No separate August 20 corporate announcement was identified.